Trial Profile
A Phase 1, Open-Label Pharmacokinetic Study to Investigate Drug Penetration in the Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement Surgery
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Jan 2019
Price :
$35
*
At a glance
- Drugs Afabicin (Primary)
- Indications Bone and joint infections; Skin and soft tissue infections; Staphylococcal infections
- Focus Pharmacokinetics
- Sponsors Debiopharm
- 17 Dec 2018 Results published in the Antimicrobial Agents and Chemotherapy
- 21 Aug 2017 Status changed from recruiting to completed.
- 24 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Jul 2017.